TD Cowen lowered the firm’s price target on ArcBest (ARCB) to $105 from $109 and keeps a Hold rating on the shares. The firm said Q4 results ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares closed last ...
Investors see "customer silicon and Nvidia as the AI chip market going forward," said Ryuta Makino, analyst at AMD investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback